J. Jeff Schwegman, Ph.D. founded AB BioTechnologies in February of 2008. Dr. Schwegman had over 16 years of experience working in the contract development/manufacturing pharmaceutical industry before launching AB BioTechnologies, a teaching and consulting firm. AB BioTechnologies started small and budget efficient in the back bedroom of Dr. Schwegman’s home. In early 2010 the first small laboratory was opened, and the company quickly grew over the next few years tripling profits each year, adding new lab equipment, and going through two lab expansions to keep up with the demand for their services.
The next expansion will be the largest yet with a new custom-built building and laboratories. The new facility will support both cGLP tox manufacturing and cGMP manufacturing of Pre-Clinical and Phase I, including the opportunity for lyophilization at the early phase Clinical Trials. AB BioTechnologies will create 20 or more jobs with this cGXP expansion to accommodate the daily operation of the business including development, manufacturing, testing, inspection, packaging, and shipping of the formulated drug products.